Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

January 22, 2024

https://www.globenewswire.com/news-release/2024/01/22/2812887/0/en/Neumora-Therapeutics-Appoints-Kaya-Pai-Panandiker-as-Chief-Commercial-Officer.html

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia.

Read more at globenewswire.com

Related news for (NMRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.